IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients
This study aimed to explore the correlation of circulating inflammatory cytokines’ levels with treatment response to etanercept (ETN) treatment in psoriasis patients.
97 moderate-to-severe plaque-psoriasis patients were continuously recruited in this prospective cohort study, and all patients received ETN treatment. Serum samples were collected before and at 6 months (M6) after treatment, and nine inflammatory cytokines expressions were detected by enzyme-linked immuno sorbent assay. Psoriasis Area and Severity Index (PASI) score was evaluated at baseline (M0), 1 month (M1), 3 months (M3) and M6 after treatment, and the corresponding PASI 75/90 responses’ rates were calculated.
Tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-12, IL-17A, IL-22, IL-23, and IL-32 levels were reduced, while IL-10 level was elevated at M6 after ETN treatment compared to baseline. PASI 75/90 responses’ rates to ETN were 69.1 and 38.1% at M6, respectively. IL-1β and IL-17A levels were elevated in PASI 75-response patients compared to PASI 75 non-response patients, while IL-17A level was also increased in PASI 90-response patients compared to PASI 90 non-response patients. Multivariate logistic regression revealed that IL-1β, IL-17A and combined phototherapy during study predicted higher, while previous systemic biologic treatment predicted lower PASI 75 response to ETN independently. In addition, IL-17A independently predicted higher PASI 90 response to ETN as well.
IL-1β, IL-17A, and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to ETN independently in psoriasis patients.
KeywordsInflammatory cytokines Psoriasis Treatment response PASI score
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflict of interest.
- Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P (2018) Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermatol Treat. https://doi.org/10.1080/09546634.2018.1467536 CrossRefGoogle Scholar
- Motolese A, Chiaravalloti V, Cerati M, Oldrini R, Mola F, Passi A (2017) Interleukin levels and macrophagic density in periumbilical fat tissue in patients affected by moderate-to-severe psoriasis with metabolic syndrome, before and after etanercept treatment. G Ital Dermatol Venereol 152:342–347. https://doi.org/10.23736/S0392-0488.16.05235-4 CrossRefPubMedGoogle Scholar
- Xie F et al (2017) Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban 37:943–947. https://doi.org/10.1007/s11596-017-1832-7 CrossRefPubMedGoogle Scholar